drugset / Trial / NCT01631227
Comparison of the Effect of Eprosartan and Eprosartan Mesylate on Blood Pressure in Essential Hypertension
Phase 3
Completed
665 enrolled
Abbott
Quintiles, Inc. · collabSynexus · collabauthor! et al. BV · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Aim of this study is to compare the blood pressure lowering effect of a new drug formulation of eprosartan. Eprosartan belongs to a class of blood pressure lowering agents used worldwide since years with proven efficacy. The new formulation is compared to the currently marketed eprosartan tablet. Equivalent efficacy in blood pressure lowering effects should be demonstrated.
Timeline
- Start
- 2012-06
- Primary completion
- 2013-04
- Completion
- 2013-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Eprosartan | Small molecule | 450 mg | — |
| Subject | Eprosartan | Small molecule | 600 mg | — |